$XRTXF XORTX Therapeutics Moves Toward Phase 3 Trials to Help with an "Orphan" Kidney Disease and COVID-19 Kidney Injuries.
eResearch initiated coverage with a "Speculative Buy" rating and one-year price target of $2.30. https://api.quotemedia.com/supplement/news-st...8654212797
(0)
(0)
XORTX Therapeutics Inc. (XRTX) Stock Research Links